Parnassus Investments, LLC Biomarin Pharmaceutical Inc Transaction History

Parnassus Investments, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$83.81 - $99.0 $81.8 Million - $96.7 Million	-976,347 Reduced 52.79%	873,001 $76.2 Million
Q4 2023 Feb 12, 2024	SELL	$76.22 - $98.51 $37.3 Million - $48.2 Million	-489,181 Reduced 20.92%	1,849,348 $178 Million
Q4 2022 Jan 30, 2023	SELL	$80.93 - $108.63 $18.4 Million - $24.7 Million	-227,551 Reduced 8.87%	2,338,529 $242 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $17.7 Million - $20.9 Million	-215,340 Reduced 7.74%	2,566,080 $218 Million
Q2 2022 Aug 05, 2022	BUY	$71.48 - $86.85 $3.97 Million - $4.82 Million	55,490 Added 2.04%	2,781,420 $230 Million
Q4 2021 Feb 11, 2022	BUY	$71.72 - $91.47 $2.94 Million - $3.76 Million	41,056 Added 1.53%	2,725,930 $241 Million
Q1 2021 May 06, 2021	BUY	$74.73 - $90.69 $87.1 Million - $106 Million	1,165,923 Added 76.76%	2,684,874 $203 Million
Q4 2020 Feb 10, 2021	BUY	$72.61 - $90.2 $96.7 Million - $120 Million	1,331,882 Added 711.97%	1,518,951 $133 Million
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $7 Million - $12.8 Million	97,349 Added 108.5%	187,069 $14.2 Million
Q2 2020 Aug 12, 2020	BUY	$79.55 - $124.22 $7.14 Million - $11.1 Million	89,720 New	89,720 $11.1 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Parnassus Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Parnassus Investments, LLC with notifications on news.